Endo Inc. (NDOI)

Market Cap	2.19B
Revenue (ttm)	1.79B
Net Income (ttm)	3.55B
Shares Out	76.21M
EPS (ttm)	21.44
PE Ratio	1.41
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,600
Average Volume	142,522
Open	28.75
Previous Close	28.75
Day's Range	28.75 - 28.75
52-Week Range	22.50 - 29.75
Beta	n/a
RSI	70.42
Earnings Date	Mar 7, 2025

About Endo Inc.

Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. It operates through four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment offers products for the treatment of conditions in urology, orthopedics, and endocrinology. Its products include XIAFLEX, a non-surgical treatment for Peyronie’s Disease for adult men with a collagen plaque an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 2,931
• Stock Exchange: OTCMKTS
• Ticker Symbol: NDOI

Financial Performance

In 2023, Endo Inc.'s revenue was $2.01 billion, a decrease of -13.25% compared to the previous year's $2.32 billion. Losses were -$2.45 billion, -16.19% less than in 2022.